Here is the latest investor presentation for BarFresh Food Group, Inc.….GREAT look at how far the company has come and more important how much opportunity lies ahead!
NBT Two-Minute Drill with David Hall, CEO of Replicel Life Sciences
January 30, 2012
We recently interviewed David Hall, CEO of Replicel Life Sciences Inc. (OTCBB:REPCF), on their upcoming Phase I/IIa clinical trial results “reveal” 90 or so days away.
By Tobin Smith|January 30, 2012, 12:11pm GMTJan 30 2012
RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB: REPCF) is pleased to report that the six-month post injection follow-up period of its TS001-2009 clinical trial is nearing completion.
